Xuan-Yuan Sword VII
SOFTSTAR · 2020 · $34.99 · Action · deal grade B
Measured on 2026-10-04 18:26 UTC. The whole catalog is re-measured daily; a game that just launched can move fast between passes.
- Estimated net residual revenue: $667 to $1.0k per month
- Opportunity: $1.5k per month at x1.85 dormancy
- Estimated lifetime owners: 340.0k
- 63% positive across 9576 reviews · 4.4 reviews/month
Why it's flagged
- Developer silent for 5.1 years
- Studio inactive: no public activity across 1 tracked titles
- Last discounted 9 months ago, 1 sales in the last 12 months
- Proven demand elasticity: x1.8 review velocity during past deep sales
Analyst notes (AI-assisted)
Note written 2026-08-25; the live figures above take precedence over any numbers in it.
Xuan-Yuan Sword VII is a 2020 action RPG from SOFTSTAR, the seventh entry in a long-running Chinese fantasy franchise.
This title sits in a quiet zone: it generated solid lifetime revenue across a modest but stable playerbase, yet shows minimal developer engagement for nearly five years. The franchise carries cultural weight in East Asian markets and casual Western recognition. For a specialized publisher or studio with Mandarin-language expertise and interest in dormant IP revival, the combination of established fan goodwill (62% positive, 96% achievement completion) and low promotional friction (only 2 discounts in 12 months) makes it a candidate for regional relaunch or localization investment, provided the developer or IP holder can be engaged. Most realistic play: licensing.
- Risk: Developer studio status is flagged as inactive; confirming rights ownership and negotiating terms could be the highest barrier.
- Risk: Negative sentiment trajectory (down 4.4 points) and story reception critiques suggest the franchise may have lost narrative momentum relative to earlier entries.
- Risk: No developer updates in nearly five years means localization, bug fixes, or platform expansion would require external resources.
This case as Markdown · Estimates carry ±30-50% error per title.